Japan's Ab market set to grow three-fold
The Japanese market for antibody pharmaceuticals such as rheumatoid arthritis drugs and anticancer agents will expand about three-fold to 340.0 billion yen ($3.2 billion) in 2017 from 113.0 billion yen in 2007, according to a recent survey by Fuji Keizai, a Tokyo-based market research company.
In 2008, the sector increased 35.4% in value to 153.0 billion yen compared with the previous year, thanks to good performances from RA drugs, antivirals and anticancer agents. This upward trend is expected to continue to around 2010.
Further boost from new indications
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze